September 24, 2020

The Niche

Knoepfler lab stem cell blog

Alliance for Regenerative Medicine (ARM)

5 min read

The FDA has stem cell clinics squarely on its radar screen now and it’s pulling the trigger with many letters going out to this problematic industry. In the past, sometimes years went by with no letters at all or one letter in total to stem cell clinics so this marks a major shift. Background on lead-up to wave of FDA activity I count 7 letters in a less than two-month span from mid-March to now, which may be the most in history in the …Read More

3 min read

Could various kinds of cell therapy help patients with COVID-19? A variety of cell therapies, mostly focused on mesenchymal stromal/stem cells (MSCs), have gotten cleared quickly in the U.S., China, and Israel and possibly other countries to be tested in patients with the novel coronavirus. I hope at least one proves helpful. It’s mostly a long shot, but some investigational products seem relatively speaking more promising than others. Here are some of the main developments as of April 13, 2020. I will likely update …Read More

3 min read

I keep a yearly hub of stem cell & regenerative medicine meetings here on The Niche. Below I’ve pasted the list for 2019, which continues to grow. If you don’t see yours listed, send me an email with the info including a link (knoepflerATucdavisDOTedu). These meeting listings are not endorsements and I try to make this list fairly comprehensive, but if you see a clearly predatory meeting, please email me and I’ll look into taking it off the list. 2019 stem cell and regenerative …Read More

2 min read

In the past month or two there has been a steady stream of good news in the stem cell and regenerative medicine world. Here are three examples. Fate Therapeutics announced the first US IND for an induced pluripotent stem cell (IPSC)-related product. Its cleared product, FT500, is an off-the-shelf natural killer-based cancer immunotherapy. I expect more to come in the next couple years so good news now and likely more to come. IPSC-based trials are picking up in Japan too with trials related to …Read More